Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral therapy for the disease.

Wondering what’s on in London? Don’t sweat it, there’s lots to keep you busy. There are always so many things to do in the Big Smoke, so we’re here to make your life a little easier by bringing you ...